In a new study published in the New England Journal of Medicine, researchers led by Charis Eng, MD, PhD and Pier Paolo Pandolfi, MD, PhD, FRCP determined that mutations of the WWP1 gene may also drive ...
Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with advanced relapsed/refractory solid tumors, lymphoma, or ...
In this MedPage Today video from the recent San Antonio Breast Cancer Symposium (SABCS), Gaia Griguolo, MD, of the Veneto Institute of Oncology in Padua, Italy, presents findings from a study ...
CGP identifies TP53 and SMAD4 mutations as negative prognostic markers, while PTEN mutations correlate with improved survival in CRC patients. Despite no significant survival advantage, CGP-guided ...
Hereditary breast cancer results from inherited mutations, primarily in BRCA1 and BRCA2, increasing lifetime cancer risk. Additional genes like TP53, PTEN, PALB2, CHEK2, and ATM also contribute to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback